TMDX
Company Description
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.49M | 441.54M | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.68M | 6.21M |
| Net Income | 190.29M | 35.46M | (25.03M) | (36.23M) | (44.22M) | (28.75M) | (33.55M) | (23.76M) | (20.82M) | (24.07M) |
| EPS | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Free Cash Flow | 133.59M | (80.94M) | (192.09M) | (57.72M) | (32.38M) | (30.72M) | (32.45M) | (26.40M) | (23.36M) | (25.59M) |
| FCF / Share | 3.93 | -2.44 | -5.91 | -1.95 | -1.17 | -1.24 | -2.28 | -1.37 | -1.61 | -1.77 |
| Operating CF | 192.84M | 48.80M | (13.03M) | (45.82M) | (28.86M) | (30.27M) | (32.29M) | (25.98M) | (23.10M) | (24.11M) |
| Total Assets | 1.07B | 804.08M | 706.05M | 277.15M | 134.89M | 152.03M | 105.30M | 42.16M | 37.00M | 58.10M |
| Total Debt | 469.69M | 518.29M | 515.95M | 67.56M | 43.80M | 34.66M | 34.15M | 33.67M | 8.65M | 8.41M |
| Cash & Equiv | 488.37M | 336.65M | 394.81M | 201.18M | 25.58M | 24.58M | 20.09M | 20.24M | 11.94M | 9.84M |
| Book Value | 473.10M | 228.60M | 137.20M | 187.38M | 67.85M | 103.89M | 54.65M | (4.83M) | (168.72M) | 38.79M |
| Return on Equity | 0.40 | 0.16 | -0.18 | -0.19 | -0.65 | -0.28 | -0.61 | N/A | N/A | -0.62 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.93M | 160.76M | 143.82M | 157.37M | 143.54M | 121.62M | 108.76M | 114.31M | 96.85M | 81.17M | 66.43M | 52.47M |
| Net Income | 7.32M | 105.38M | 24.32M | 34.91M | 25.68M | 6.86M | 4.22M | 12.19M | 12.20M | 4.03M | (25.42M) | (1.00M) |
| EPS | 0.21 | 3.08 | 0.71 | 1.03 | 0.76 | 0.20 | 0.13 | 0.37 | 0.37 | 0.12 | -0.78 | -0.03 |
| Free Cash Flow | (12.12M) | 19.00M | 61.95M | 82.53M | (29.89M) | 6.06M | (41.35M) | 1.96M | (47.61M) | (33.51M) | (114.59M) | (7.18M) |
| FCF / Share | -0.35 | 0.56 | 1.82 | 2.43 | -0.89 | 0.18 | -1.24 | 0.06 | -1.45 | -1.03 | -3.51 | -0.22 |
| Operating CF | 24.53M | 34.51M | 69.57M | 91.61M | (2.85M) | 19.66M | 6.86M | 25.72M | (3.44M) | 8.30M | (6.87M) | (5.80M) |
| Total Assets | 1.43B | 1.07B | 946.03M | 890.52M | 837.53M | 804.08M | 785.57M | 758.58M | 723.83M | 706.05M | 689.23M | 690.36M |
| Total Debt | 863.41M | 469.69M | 519.35M | 518.82M | 518.41M | 518.29M | 518.15M | 516.49M | 516.22M | 515.95M | 515.65M | 515.01M |
| Cash & Equiv | 461.74M | 488.37M | 466.17M | 400.57M | 310.14M | 336.65M | 330.09M | 362.75M | 350.22M | 394.81M | 427.11M | 582.21M |
| Book Value | 494.01M | 473.10M | 355.20M | 318.10M | 266.31M | 228.60M | 209.92M | 189.89M | 159.47M | 137.20M | 126.46M | 145.21M |
| Return on Equity | 0.01 | 0.22 | 0.07 | 0.11 | 0.10 | 0.03 | 0.02 | 0.06 | 0.08 | 0.03 | -0.20 | -0.01 |
